Specializes in developing novel drug candidates for the treatment of central nervous system disorders and oncology.
Bionomics Limited, headquartered in Eastwood, Australia, is a dynamic clinical stage biopharmaceutical company dedicated to the discovery and development of innovative drug candidates. Since its incorporation in 1996, the company has focused on advancing treatments for central nervous system disorders and cancers. At the forefront of its pipeline is BNC210, a promising drug candidate classified as a negative allosteric modulator of the a7 nicotinic acetylcholine receptor. BNC210 is currently undergoing phase 2 clinical trials for social anxiety disorder and phase 2b trials for post-traumatic stress disorder, demonstrating Bionomics' commitment to addressing critical unmet medical needs.
In addition to BNC210, Bionomics is actively developing other promising therapies. Notably, BNC101, a monoclonal antibody targeting cancer stem cells, has successfully completed phase 1 clinical trials, marking significant progress in the company's oncology portfolio. Another key candidate, BNC105, is underggoing phase 2 trials for refractory colorectal cancer and phase 1 trials for relapsed/refractory chronic lymphocytic leukemia, highlighting Bionomics' diverse approach to tackling cancer treatment challenges.
Driven by a robust research and development strategy, Bionomics Limited continues to innovate in the biopharmaceutical industry, aiming to deliver transformative therapies that improve patient outcomes globally. With a strong emphasis on scientific rigor and clinical advancement, the company remains dedicated to making meaningful contributions to healthcare through its novel drug discovery efforts.